ViralGen

Viralgen is a top player in gene therapy. They focus on making lots of adeno-associated virus (AAV) for cell and gene treatments. Started in 2017, Viralgen is part of AskBio Inc. and Bayer AG group. They use the Pro10 suspension manufacturing platform to make high amounts of all AAV types. This makes clinical development and selling the products easier. You can find them in San Sebastian, Spain. Their advanced facility has three top-notch production areas with over 2000L capacity, approved by AEMPS.

Key Features

Viralgen offers many services like help with rules and laws, quality testing, and checking if things can be made bigger. Their platform, which includes the AskBio Pro10 HEK293 cell line, is known for giving high results. It helps make and clean AAV from small to large amounts, pack them in different ways, and check quality with most tests done in-house. They also help with rules and laws around the world for every step.

Viralgen makes adeno-associated virus (AAV) gene therapies using AskBio''s Pro10 process. This method is fast, big, gives high results, and is accurate. Their current setup includes three modern production areas to make three different products at the same time. They have tools to make 50L for safety and other studies with full support for research and safe production together. They use tanks of 50L, 250L, and 500L to grow cells with 1250 liters just for AAV production. They also have in-house labs to check quality.

Viralgen plans to grow and support up to 2000L scale for selling by the end of 2021.

Benefits

Viralgen''s advanced production uses Pro10 technology with HEK293 cells for pure AAV making. They use digital tools like SAP and LIMS for real-time watching. They also use CRM, DMS, and QMS systems for quality and customer care, with safety steps and work toward ISO 27001. They make easy-to-use dashboards for checking and deciding, use math models and digital twins to guess product making, and have a Customer Portal to help clients.

Use Cases

Viralgen works with the CTNNB1 Foundation to make a gene therapy for CTNNB1 Syndrome. This rare genetic issue affects how kids move and think. The goal is to improve movement, talking, and life quality for these patients.

Viralgen also works with the Vallabh/Minikel Lab and the Deverman Lab at the Broad Institute. They make an AAV gene therapy for prion disease. This work makes new virus covers to send genes to the brain well, aiming to slow or stop prion disease.

Viralgen gives products for gene therapy research. They aim to treat rare and very rare diseases by working with Columbus Children''s Foundation and Fundacion Columbus. They also help early research for treatments of rare diseases like drug-resistant focal epilepsy, Spastic Paraplegia 50, and Charcot-Marie-Tooth disease type 4J.

Cost/Price

The cost/price of the product is not given in the article.

Funding

The funding details of the product from investors is not given in the article.